Genovis AB (FRA:5GV) ROCE % : 7.10% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Genovis AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genovis AB's annualized ROCE % for the quarter that ended in Dec. 2024 was 7.10%.

Genovis AB ROCE % Historical Data

The historical data trend for Genovis AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB ROCE % Chart

Genovis AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

3.77

21.88

6.45

26.94

15.92

Genovis AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															0.54	22.90	3.56	30.25	7.10

Genovis AB ROCE % Calculation

Genovis AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	3.976	/	( ( (25.823 - 1.897)	+	(28.464 - 2.451) )	/ 2 )
	=	3.976	/	( (23.926	+	26.013)	/ 2 )
	=	3.976	/	24.9695
	=	15.92 %

Genovis AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	1.852	/	( ( (28.129 - 1.957)	+	(28.464 - 2.451) )	/ 2 )
	=	1.852	/	( ( 26.172	+	26.013 )	/ 2 )
	=	1.852	/	26.0925
	=	7.10 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Genovis AB (FRA:5GV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genovis AB ROCE % Related Terms

Thank you for viewing the detailed overview of Genovis AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genovis AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (FRA:5GV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GENO:Sweden

Address

Scheelevagen 2, Box 790, Lund, SWE, SE-220 07

Website

https://www.genovis.com

Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.

Genovis AB Headlines

No Headlines